Caliway Biopharmaceuticals C, TW0006919004

Caliway Biopharmaceuticals stock: 52-week low leaves Caliway stock at TWD 73.80

Published on 10/22/2026 at 17:08 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

November 11 results are next. Caliway Biopharmaceuticals stock costs TWD 73.80 on October 22, 2026, down 2.89 percent versus TWD 76.00.

Reporting date November 11, 2026

Investing.com lists November 11, 2026 as the next results date.
The latest quarter produced TWD 3.57 million in revenue and a TWD 222.52 million net loss.
Caliway Biopharmaceuticals stock last traded at TWD 73.80 on October 22, 2026, down 2.89 percent versus TWD 76.00.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals stock is approaching its next scheduled reporting date, with results listed for November 11, 2026. Investing.com gives that date as the companys next earnings release. The stock last traded at TWD 73.80 on the Taiwan Stock Exchange on October 22, 2026 at 1:30 p.m. CST, down 2.89 percent from TWD 76.00.

November 11 is the next date

The scheduled report will cover the period ending September 2026, according to Investing.com. The same calendar lists the prior release on August 4, 2026, giving investors a concrete timetable for the next update.

Revenue remains a small base

For the latest quarter ended June 2026, Caliway reported TWD 3.57 million in revenue and a TWD 222.52 million net loss. Revenue was TWD 0.00 million in the previous quarter, while the loss widened from TWD 107.75 million, figures carried by Investing.com. The comparison points to a development-stage business whose financial statement remains dominated by research spending.

Price sits at the yearly low

The October 22, 2026 quote of TWD 73.80 also marked the lower end of the reported 52-week range of TWD 73.80 to TWD 188.00. The market value stood at TWD 114.9 billion on the same date, while trading volume reached 2,728,647 shares. These figures place the latest price at the bottom of the annual range rather than near its midpoint.

What does the next report add?

The November release should update the September quarter and provide the next dated checkpoint for CBL-514 development. Caliway said in an October 2, 2026 investor release that phase 3 recruitment had started, with the program testing CBL-514 for nonsurgical abdominal fat reduction; the companys release also described the phase 3 studies as randomized and placebo-controlled. Caliway Biopharmaceuticals said first results were expected at the end of 2027.

Stock position

Caliway Biopharmaceuticals last traded at TWD 73.80 on the Taiwan Stock Exchange on October 22, 2026 at 1:30 p.m. CST, down 2.89 percent versus TWD 76.00.